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fractures. Considering the nearly equal risk of 
secondary surgical procedures and the modest 
benefit in functional outcome, should we aban-
don the use of total hip arthroplasty in the treat-
ment of hip fractures? Even if the benefits seem 
smaller than we previously thought, patients with 
high physical demands and a long remaining 
life expectancy should probably still be consid-
ered for treatment with total hip arthroplasty. 
Yet the expected remaining lifetime of those pa-
tients who potentially could benefit most from a 
total hip arthroplasty is much longer than the 
2-year follow-up period used in the HEALTH trial. 
However, the number of secondary procedures 
after hemiarthroplasty may increase with longer 
follow-up. Therefore, one hopes that the HEALTH 
investigators will be able to provide long-term 
results from their trial in the future. Such data 
would be an even more important contribution 
to the knowledge base that supports hip-fracture 
treatment. There is still a need for large random-
ized, controlled trials or registry-based random-
ized clinical trials with greater numbers of pa-
tients in order to identify how factors such as 
patient activity level, biologic age, and remain-
ing life expectancy influence the risk of second-
ary surgical procedures and functional outcome 
after hemiarthroplasty and total hip arthroplas-
ty. Until then, in light of the results of the trial 
by Bhandari et al., we should probably be restric-
tive in the selection criteria for total hip arthro-
plasty for patients with hip fractures.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
From the Department of Orthopedic Surgery, Haukeland Uni-
versity Hospital, and the Institute of Clinical Medicine, Univer-
sity of Bergen — both in Bergen, Norway. 
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Typhoid fever is caused by fecal–oral transmis-
sion of Salmonella enterica serovar Typhi (S. Typhi). 
It has been a deadly companion to mankind for 
centuries, affecting 10.9 million persons and re-
sulting in an estimated 116,800 deaths per year.1 
Although vaccines against typhoid have been avail-
able for more than a century and have been shown 
to be protective,2,3 the approved vaccines (inject-
able Vi polysaccharide and oral, live-attenuated 
Ty21a typhoid vaccines) have not been useful in 
populations with a high typhoid burden, particu-
larly in young children.4 To address this shortfall, 
the Bill and Melinda Gates Foundation, as well as 
other donors, has supported the development of 
new typhoid conjugate vaccines (TCVs), generated 
data on disease burden, and coordinated with 
international stakeholders to introduce the vac-
cine in countries where typhoid fever is endemic.
Typbar-TCV was developed by Bharat Biotech 
International in India and was prequalified by 
the World Health Organization (WHO)3 on the 
basis of immunogenicity and evidence of protec-
tion (55% efficacy) in a typhoid human challenge 
model.5 In this issue of the Journal, Shakya et al.6 
report that this vaccine was immunogenic and 
efficacious against blood culture–confirmed ty-
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phoid fever, with an estimated vaccine efficacy 
of 81.6% at 12 months, in a trial involving chil-
dren who were between 9 months and 16 years 
of age.
Data from African and Asian surveillance 
studies were used by the WHO Strategic Advi-
sory Group of Experts to recommend the use of 
TCVs in countries where typhoid fever is en-
demic.2,4 Subsequently, TCVs were added to vac-
cines subsidized by Gavi, the Vaccine Alliance. 
The Typbar-TCV vaccine is already commercially 
available in India. Other large studies, such as 
the TCV introduction program in Navi Mumbai, 
India (ClinicalTrials.gov number, NCT03554213), 
are currently ongoing,7 and introduction of the 
vaccine through Gavi subsidies in Asian and 
African countries is also under way. Ongoing 
and planned clinical trials are geared toward 
systematic assessment of vaccine performance 
and addressing unanswered scientific questions 
regarding effectiveness, herd immunity, cost-
effectiveness, and the effect of the vaccine on 
antimicrobial resistance. The trial by Shakya 
and colleagues, combined with evidence of safety 
and immunogenicity in other trials,7 provides 
support for broader introduction of TCVs in coun-
tries where typhoid is endemic. The national and 
international stakeholders involved in decisions 
regarding the introduction of TCV await results 
from longer-term follow-up to determine wheth-
er protection elicited by TCVs exceeds that of 
existing Vi polysaccharide and live-attenuated 
oral vaccines.
Typhoid fever has been successfully treated 
with antimicrobial agents since early in the anti-
microbial era, but sustained antibiotic pressure 
through large-scale (over)use has created multi-
drug-resistant and extensively drug-resistant 
(XDR) typhoid strains that have spread in India, 
Bangladesh, and Pakistan.8 Patients with severe 
S. Typhi infection caused by a resistant strain 
often have prolonged hospital stays and limited 
treatment options. Moreover, the presenting signs 
and symptoms of typhoid fever are nonspecific, 
and diagnostic testing is hampered by the poor 
sensitivity and limited availability of existing 
tests, including blood cultures (which, although 
insensitive, are considered to be the best avail-
able test for typhoid fever), particularly in resource-
limited areas. Thus, patients with suspected ty-
phoid fever in areas where typhoid is endemic 
frequently receive antimicrobial agents from health 
care providers, and unnecessary antimicrobial 
pressure is added to resident bacterial popula-
tions. To date, XDR typhoid is confined to India, 
Bangladesh, and Pakistan, where newer antibiot-
ics are available.8 Yet, it is easy to envision that 
the introduction of XDR S. Typhi strains into 
Africa, with underresourced health care systems 
and a lack of treatment options, could lead to a 
scenario involving considerable morbidity and 
mortality.
Additional large-scale trials are under way to 
provide data on vaccine performance in other 
geographic areas. The Typhoid Vaccine Accelera-
tion Consortium (TyVAC) is evaluating TCV in 
Dhaka, Bangladesh (in a cluster-randomized tri-
al), Blantyre, Malawi (in an individually random-
ized trial), and Ouagadougou, Burkina Faso (in 
coadministration studies).9 Researchers in the 
THECA (Effect of a Novel Typhoid Conjugate 
Vaccine in Africa: A Multicenter Study in Ghana 
and the Democratic Republic of the Congo) trial 
are in close alignment with the TyVAC, conduct-
ing a cluster-randomized trial in Agogo, Ghana, 
and a large-scale trial of vaccine effectiveness in 
Kisantu, Democratic Republic of Congo.10 This 
compendium of data for stakeholders in the in-
troduction of vaccine may be used to target in-
terventions to protect as many persons as pos-
sible given the existing constraints on resources.
Shakya and colleagues have made an impor-
tant contribution to the global fight against 
S. Typhi infection, but global health is about im-
pact. If further studies support and extend these 
results, how can a corresponding reduction in the 
burden of typhoid disease and death be achieved 
most efficiently?
Disclosure forms provided by the authors are available with 
the full text of this editorial at NEJM.org.
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(F.M., J.H.K.); and the University of Cambridge, Cambridge, 
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